Recent Advances in Neuromyelitis Optica Spectrum Disorder: Pathogenesis, Mechanisms and Potential Treatments

(E-pub Ahead of Print)

Author(s): Yi Du, Kaijun Li, Wei Liu, Ruitong Song, Meifeng Luo, Jianfeng He, Xiaoyu Xu*, Xiaosheng Qu*

Journal Name: Current Pharmaceutical Design

Become EABM
Become Reviewer
Call for Editor


Neuromyelitis optica spectrum disorder (NMOSD) is an acute or subacute demyelinating disease that affects mainly the optic nerve and spinal cord. A major proportion of NMOSD cases have a relationship with autoimmunity to aquaporin 4 (AQP4) found on the central nervous system. NMOSD can occur repeatedly, causing symptoms such as decreased vision and weakness of limbs. The main goal of current therapy is to relieve acute symptoms and prevent recurrence of the disease. Without timely and appropriate treatment, the recurrence and disability rates are high. In the present work, we review recent advances in the diagnosis and treatment of patients with NMOSD, as well as the pathogenesis and mechanisms of AQP4-IgG-seropositive NMOSD.

Keywords: Devic’s disease, AQP4, autoimmunity, pathogenesis, therapy, NMOSD

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1381612827666210329101335
Price: $95

Article Metrics

PDF: 176